GYRE
HEALTHCAREGyre Therapeutics Inc.
What's Moving GYRE Today?
No stock-specific AI insight has been generated for GYRE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.13
Fundamentals
Trading
GYRE News
25 articles- Gyre Therapeutics Inc (GYRE) Institutional ConfidenceTradingKey·Jun 18, 2026
- US High Growth Tech Stocks To WatchYahoo Finance·May 28, 2026
- New Strong Sell Stocks for May 27thYahoo Finance·May 27, 2026
- Gyre Therapeutics stock (KYG4200L1031): Low short interest signals stability amid pharma peersAD HOC NEWS·May 14, 2026
- Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis TreatmentYahoo Finance·May 12, 2026
- Gyre Therapeutics (GYRE) CSO discloses new Series B stakeStock Titan·May 8, 2026
- Gyre Therapeutics (GYRE) EVP details multiple stock option grantsStock Titan·May 8, 2026
- Gyre Therapeutics (GYRE) GC holds option for 47,530 sharesStock Titan·May 8, 2026
- Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateYahoo Finance·May 7, 2026
- Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyYahoo Finance·May 4, 2026
- Exploring Three High Growth Tech Stocks In The US MarketYahoo Finance·Mar 27, 2026
- Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentYahoo Finance·Mar 17, 2026
- Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss EstimatesYahoo Finance·Mar 12, 2026
- Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 12, 2026
- Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 9, 2026
- Gyre Therapeutics to acquire Cullgen in $300M all-stock transactionYahoo Finance·Mar 3, 2026
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Mar 2, 2026
- Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and PipelineYahoo Finance·Mar 2, 2026
- Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 25, 2026
- High Growth Tech Stocks in US for February 2026Yahoo Finance·Feb 11, 2026
- Discovering Undiscovered Gems in the US MarketYahoo Finance·Jan 26, 2026
- High Growth Tech Stocks To Watch In The US Market January 2026Yahoo Finance·Jan 13, 2026
- Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA MeetingYahoo Finance·Jan 5, 2026
- Undiscovered Gems in the US Market to Explore This December 2025Yahoo Finance·Dec 26, 2025
All 25 articles loaded
Price Data
52-Week Range
$6.13
Fundamentals
Trading
About Gyre Therapeutics Inc.
Gyre Therapeutics Inc. is an innovative biopharmaceutical company dedicated to advancing therapies for rare and complex diseases through its proprietary platform, which integrates gene therapy and precision medicine. The company boasts a promising pipeline focused on addressing significant unmet medical needs and improving patient outcomes. With a strong commitment to scientific excellence and strategic collaborations, Gyre is strategically positioned for impactful growth in the biopharmaceutical landscape. As it continues to enhance its research and development initiatives, Gyre stands to transform treatment paradigms for patients facing challenging health conditions.